Latest Biotech News

Revolution Medicines reported survival results from its Phase 3 pancreatic adenocarcinoma study of daraxonrasib, a daily oral KRAS inhibitor. In the trial, patients lived a median of 13.2 months...

FDA’s Office of Prescription Drug Promotion (OPDP) is stepping up enforcement activity, focusing scrutiny on advertising tone, imagery, and whether promotional claims match clinical evidence. The...

FDA’s budget proposal includes a set of policy priorities, including a move to make pediatric priority review vouchers permanent. The budget plan also signals continued pressure on agency advisory...

The Polish Population Genomics Project secured PLN 248 million to sequence up to 7,000 individuals and build a national infrastructure for genomic research. Funders include support routed through...

Kailera Therapeutics priced an upsized IPO to raise $625 million, targeting a late-stage obesity pipeline led by ribupatide (KAI-9531), a once-weekly GLP-1/GIP dual agonist peptide. The offering...

UCB agreed to acquire Neurona for up to $1.2 billion, aiming to broaden beyond its small-molecule epilepsy base. The deal is designed to diversify its seizure treatment portfolio with a...

Roche outlined a route to EMA approval for its Duchenne muscular dystrophy gene therapy Elevidys (delandistrogene moxeparvovec) by announcing a further global Phase 3 trial. The study is intended...

Alamar Biosciences began trading on Nasdaq after pricing a $220 million IPO, signaling continued demand for proteomics platforms that can move toward regulated diagnostics. The company plans to...

Biopharma layoffs and projected cuts moderated year over year in Q1 2026, but total affected employees rose. Reporting from BioSpace indicates 35 companies made or planned cuts in Q1 2026 versus...

10x Genomics launched Atera, a whole-transcriptome spatial biology instrument designed to close gaps in throughput and measurement trade-offs compared with existing spatial tools. The company...

Revolution Medicines’ daraxonrasib posted a major survival benefit in a Phase 3 pancreatic cancer trial, strengthening the case for a new class of KRAS-targeted therapies in a disease that...

A separate report on Revolution Medicines’ KRAS/pan-RAS momentum highlights how the latest clinical outcome has shifted market perceptions around potential corporate actions. The story frames the...

Roche is pressing its case with the EMA for its Duchenne muscular dystrophy gene therapy Elevidys (delandistrogene moxeparvovec) by initiating a further global Phase 3 trial. The study aims to...

Neomorph raised $100 million in a Series B round to advance its oral molecular glue degrader NEO-811 through clinical development in clear cell renal cell carcinoma. The company is funding an...

Transformative Biotech said it is advancing extraction-free PCR chemistry aimed at cutting a major bottleneck in molecular testing: the sample extraction step. The approach is being marketed to...

Beeline Medicines launched with a $300 million Series A led by Bain Capital to pursue a portfolio of five in-licensed programs from Bristol Myers Squibb targeting immune-mediated diseases. The...

Kailera Therapeutics priced an upsized US biopharma IPO, raising $625 million and setting a new record for U.S. drug-company debut. The company priced 39 million shares at $16 apiece, with a full...

10x Genomics unveiled Atera, a new spatial instrument announced at AACR, positioning it as a whole-transcriptome spatial biology platform designed to reduce common trade-offs across existing...

A clinical trial reported progress on using donor-derived regulatory dendritic cells (DCreg) to modulate immune response after living-donor liver transplantation while enabling earlier withdrawal...

Trevi Therapeutics raised $150 million through a planned equity offering as it looks to fund pipeline development and clinical progress. The report indicates the company plans to float more than...